New Edge Advisors, LLC Agios Pharmaceuticals, Inc. Transaction History
New Edge Advisors, LLC
- $20.5 Billion
- Q3 2025
A detailed history of New Edge Advisors, LLC transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 1,273 shares of AGIO stock, worth $55,566. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,273
Previous 1,273
-0.0%
Holding current value
$55,566
Previous $42,000
21.43%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding AGIO
# of Institutions
256Shares Held
63.8MCall Options Held
2.06MPut Options Held
911K-
Farallon Capital Management LLC San Francisco, CA5.78MShares$252 Million1.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.6MShares$245 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.86MShares$212 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V83.71MShares$162 Million3.19% of portfolio
-
Erste Asset Management Gmb H Vienna, C42.76MShares$121 Million1.05% of portfolio
About AGIOS PHARMACEUTICALS, INC.
- Ticker AGIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,818,000
- Market Cap $2.39B
- Description
- Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...